Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Immunomedics Inc. (Nasdaq:IMMU) today announced that clinical trial results from the Phase IIb EMBLEM™ study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism (EULAR) in Rome, Italy.

The title of the presentations, followed by a link to the posters presented, are listed below:

• "Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): Results from EMBLEM™, a Phase IIb study," (http://media.globenewswire.com/cache/8057/file/8404.pdf)
   
• "BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: Results from EMBLEM™, a Phase IIb study," (http://media.globenewswire.com/cache/8057/file/8405.pdf)
   
• "The effects of the anti-CD22 monoclonal antibody epratuzumab on peripheral blood B cells and immune responses in vivo and immunoglobulin production in vitro," (http://media.globenewswire.com/cache/8057/file/8406.pdf)
   
• "Impact of systemic lupus erythematosus on patients' employment, family relationships, and overall well-being," (http://media.globenewswire.com/cache/8057/file/8407.pdf)